68 related articles for article (PubMed ID: 32336762)
1. Recent advances in chemometric modelling of inhibitors against SARS-CoV-2.
Wang Q; Lu X; Jia R; Yan X; Wang J; Zhao L; Zhong R; Sun G
Heliyon; 2024 Jan; 10(2):e24209. PubMed ID: 38293468
[TBL] [Abstract][Full Text] [Related]
2. Computational medicinal chemistry role in clinical pharmacy education: Ingavirin for coronavirus disease 2019 (COVID-19) discovery model.
Saadah LM; Deiab GIA; Al-Balas QA; Basheti IA
Pharm Pract (Granada); 2022; 20(4):2746. PubMed ID: 36793906
[TBL] [Abstract][Full Text] [Related]
3. Effect of an Inhibitor on the ACE2-Receptor-Binding Domain of SARS-CoV-2.
Sharma G; Song LF; Merz KM
J Chem Inf Model; 2022 Dec; 62(24):6574-6585. PubMed ID: 35118864
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H
J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199
[TBL] [Abstract][Full Text] [Related]
5. Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2.
Muchtaridi M; Fauzi M; Khairul Ikram NK; Mohd Gazzali A; Wahab HA
Molecules; 2020 Sep; 25(17):. PubMed ID: 32882868
[TBL] [Abstract][Full Text] [Related]
6. Design of Angiotensin-converting Enzyme 2 (ACE2) Inhibitors by Virtual Lead Optimization and Screening.
Torres JE; Baldiris R; Vivas-Reyes R
J Chin Chem Soc; 2012 Nov; 59(11):1394-1400. PubMed ID: 32336762
[TBL] [Abstract][Full Text] [Related]
7. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment.
Teralı K; Baddal B; Gülcan HO
J Mol Graph Model; 2020 Nov; 100():107697. PubMed ID: 32739642
[TBL] [Abstract][Full Text] [Related]
8. Spike protein recognizer receptor ACE2 targeted identification of potential natural antiviral drug candidates against SARS-CoV-2.
Pokhrel S; Bouback TA; Samad A; Nur SM; Alam R; Abdullah-Al-Mamun M; Nain Z; Imon RR; Talukder MEK; Tareq MMI; Hossen MS; Karpiński TM; Ahammad F; Qadri I; Rahman MS
Int J Biol Macromol; 2021 Nov; 191():1114-1125. PubMed ID: 34592225
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Evaluation of In Silico Screening Approaches in Search for Selective ACE2 Binding Chemical Probes.
Rayevsky AV; Poturai AS; Kravets IO; Pashenko AE; Borisova TA; Tolstanova GM; Volochnyuk DM; Borysko PO; Vadzyuk OB; Alieksieieva DO; Zabolotna Y; Klimchuk O; Horvath D; Marcou G; Ryabukhin SV; Varnek A
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080168
[TBL] [Abstract][Full Text] [Related]
10. Carnosine to Combat Novel Coronavirus (nCoV): Molecular Docking and Modeling to Cocrystallized Host Angiotensin-Converting Enzyme 2 (ACE2) and Viral Spike Protein.
Saadah LM; Deiab GIA; Al-Balas Q; Basheti IA
Molecules; 2020 Nov; 25(23):. PubMed ID: 33260592
[TBL] [Abstract][Full Text] [Related]
11. Structure-based pharmacophore design and virtual screening for novel angiotensin converting enzyme 2 inhibitors.
Rella M; Rushworth CA; Guy JL; Turner AJ; Langer T; Jackson RM
J Chem Inf Model; 2006; 46(2):708-16. PubMed ID: 16563001
[TBL] [Abstract][Full Text] [Related]
12. Lead- and drug-like compounds: the rule-of-five revolution.
Lipinski CA
Drug Discov Today Technol; 2004 Dec; 1(4):337-41. PubMed ID: 24981612
[TBL] [Abstract][Full Text] [Related]
13. Some recent approaches of biologically active substituted pyridazine and phthalazine drugs.
Asif M
Curr Med Chem; 2012; 19(18):2984-91. PubMed ID: 22519394
[TBL] [Abstract][Full Text] [Related]
14. Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.
Burrell LM; Burchill L; Dean RG; Griggs K; Patel SK; Velkoska E
Exp Physiol; 2012 Apr; 97(4):477-85. PubMed ID: 22198016
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
